Strong Q2 from J&J as pandemic-hit sales, profit recover

Johnson & Johnson’s second-quarter profit soared 73%, thanks to strong sales growth, particularly in its medical device and diagnostics segment, as hospitals and the health care industry as a whole continue recovering from the coronavirus pandemic

NEW YORK -- Johnson & Johnson’s second-quarter profit soared 73%, thanks to strong sales growth across all of its businesses as hospitals and the rest of the health care industry continued recovering from the coronavirus pandemic's impact. The health care giant handily topped Wall Street expectations and hiked its 2021 sales and profit forecasts sharply.. The world’s biggest maker of health care products on Wednesday reported second-quarter net income of $6.28 billion, or $2.35 per share, up from $3.63 billion, or $1.36 per share, a year earlier. Adjusted income came to $6.63 billion, or $2.48 per share, blowing past Wall Street projections for $2.28 per share.